Progress in transformation therapy for pancreatic neuroendocrine neoplasms

doi:10.3877/cma.j.issn.2095-3232.2024.04.003

Abstract

Abstract:

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms. NENs arising from the stomach, bowel and pancreas can be divided into high-differentiated neuroendocrine tumors (NET) and neuroendocrine carcinoma, among which high-differentiated NET can be subdivided into NET G1, G2 and NET G3 according to Ki-67 index, and classified into functional NET and non-functional NET according to the function of hormone secretion. NF-NET is the dominant type, manifested with elusive onset. Many patients have local progression and/or distant metastasis upon diagnosis. Transformation therapy is of significance for patients with advanced NET. In this article, common transformation therapies were summarized based on different biological behaviors of advanced tumors. According to the characteristics of different types of tumors, appropriate treatment approaches were determined. Drug combination therapy should be carried out to achieve precise and individualized treatment when necessary.

Key words: Neuroendocrine tumor, Neuroendocrine carcinoma, Transformation therapy, Preoperative treatment

Xiaowei Deng, Chenghao Shao. Progress in transformation therapy for pancreatic neuroendocrine neoplasms[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 456-460.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.04.003

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I04/456

References 44

[1]	Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors[J]. Endocr Relat Cancer, 2016, 23(9):759-767.
[2]	Shyr BS, Shyr BU, Chen SC, et al. Impact of tumor grade on pancreatic neuroendocrine tumors[J]. Asian J Surg, 2022, 45(12):2659-2663.
[3]	Donadio MD, Brito ÂB, Riechelmann RP. A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors[J]. Ther Adv Med Oncol, 2023, 15: 17588359231156218.
[4]	Das S, Pineda G, Goff L, et al. The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience[J]. Cancer Imaging, 2018, 18(1):47.
[5]	Shi M, Zhou B. Clinical characteristics and prognostic factors of early-onset pancreatic neuroendocrine tumors[J]. Cancer Control, 2021, 28: 1073274820986827.
[6]	Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331(6021):1199-1203.
[7]	Reher D, Fehrenbach U, Kayser A, et al. Localization defines streptozotocin/5-FU response in primary pancreatic neuroendocrine tumours[J]. Neuroendocrinology, 2022, 112(6):595-605.
[8]	Lu Y, Zhao Z, Wang J, et al. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis[J]. Medicine, 2018, 97(41):e12784.
[9]	Walter MA, Nesti C, Spanjol M, et al. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 11(11):CD013700.
[10]	Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors[J]. Semin Oncol, 2013, 40(1):75-83.
[11]	Lee L, Ramos-Alvarez I, Jensen RT. Predictive factors for resistant disease with medical/radiologic/liver-directed anti-tumor treatments in patients with advanced pancreatic neuroendocrine neoplasms: recent advances and controversies[J]. Cancers, 2022, 14(5):1250.
[12]	Li AY, Visser BC, Dua MM. Surgical indications and outcomes of resection for pancreatic neuroendocrine tumors with vascular involvement[J]. Cancers, 2022, 14(9):2312.
[13]	Parghane RV, Bhandare M, Chaudhari V, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors[J]. J Nucl Med, 2021, 62(11):1558-1563.
[14]	Cives M, Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract[J]. Curr Treat Options Oncol, 2017, 18(3):14.
[15]	Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors[J]. N Engl J Med, 2017, 376(2):125-135.
[16]	Chou WC, Lin PH, Yeh YC, et al. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors[J]. Int J Biol Sci, 2016, 12(12):1523-1532.
[17]	de Mestier L, Walter T, Evrard C, et al. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor[J]. Neuroendocrinology, 2020, 110(1/2):83-91.
[18]	Al-Toubah T, Pelle E, Valone T, et al. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms[J]. J Natl Compr Canc Netw, 2021, 20(1):29-36.
[19]	Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site[J]. Neuroendocrinology, 2016, 103(2):172-185.
[20]	Wang W, Zhang Y, Peng Y, et al. A ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study[J]. Neuroendocrinology, 2021, 111(8):752-763.
[21]	Arrivi G, Verrico M, Roberto M, et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis[J]. Cancer Manag Res, 2022, 14: 3507-3523.
[22]	Urso L, Nieri A, Rambaldi I, et al. Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review[J]. Endocrine, 2022, 78(2):255-261.
[23]	Tu KY, Huang YS, Lau J, et al. Adaptive Tomotherapy for locally advanced unresectable pancreatic neuroendocrine tumor: case report and literature review[J]. Front Oncol, 2022, 12:1045752.
[24]	Luo G, Javed A, Strosberg JR, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on cancer and European neuroendocrine tumor society systems[J]. J Clin Oncol, 2017, 35(3):274-280.
[25]	Frey S, Mirallié E, Le Bras M, et al. What are the place and modalities of surgical management for pancreatic neuroendocrine neoplasms? a narrative review[J]. Cancers, 2021, 13(23):5954.
[26]	Fazio N. Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: a difficult conversion from biology to the clinic[J]. World J Clin Oncol, 2015, 6(6):194-197.
[27]	Patel SP, Othus M, Chae YK, et al. A phase Ⅱ basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors[J]. Clin Cancer Res, 2020, 26(10):2290-2296.
[28]	Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma[J]. J Neuroendocrinol, 2023, 35(3):e13249.
[29]	Douangprachanh S, Joo HJ, Park HM, et al. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience[J]. Korean J Intern Med, 2022, 37(6):1216-1222.
[30]	Zhu J, Strosberg JR, Dropkin E, et al. Treatment of high-grade metastatic pancreatic neuroendocrine carcinoma with FOLFIRINOX[J]. J Gastrointest Cancer, 2015, 46(2):166-169.
[31]	Crook C, Zhang YH, Li D. Pharmacotherapeutic management of well-differentiated neuroendocrine tumors in older patients: current status and potential therapies[J]. Drugs Aging, 2022, 39(4):257-269.
[32]	Chatzellis E, Angelousi A, Daskalakis K, et al. Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms[J]. Neuroendocrinology, 2019, 109(4):333-345.
[33]	Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence[J]. Expert Opin Pharmacother, 2018, 19(8):909-928.
[34]	Kim HS, Shaib WL, Zhang C, et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases[J]. Cancer, 2018, 124(9):1992-2000.
[35]	Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review[J]. Eur J Radiol, 2018, 100:23-29.
[36]	Satapathy S, Mittal BR, Sood A, et al. 177Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience[J]. JCO Glob Oncol, 2021, 7:1167-1175.
[37]	吴峻立, 苗毅. 胰腺神经内分泌肿瘤肝转移术前评估和外科治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(1):6-10.
[38]	Zappi A, Persano I, Galvani L, et al. Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: a narrative review[J]. J Clin Med, 2023, 12(2):717.
[39]	Raj N, Valentino E, Capanu M, et al. Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated[J]. Pancreas, 2017, 46(3):296-301.
[40]	Eads JR, Catalano PJ, Fisher GA, et al. Randomized phaseⅡ study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs):ECOG-ACRIN EA2142[J]. J Clin Oncol, 2022,40(16 Suppl):4020.
[41]	Mizuno Y, Kudo A, Akashi T, et al. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms[J]. J Cancer Res Clin Oncol, 2018, 144(6):1155-1163.
[42]	Panzuto F, Rinzivillo M, Spada F, et al. Everolimus in pancreatic neuroendocrine carcinomas G3[J]. Pancreas, 2017, 46(3):302-305.
[43]	Zhou Y, Liu S, Liu C, et al. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor[J]. Int J Biol Sci, 2021, 17(14):3760-3775.
[44]	梅文通, 李非. 胰腺神经内分泌肿瘤手术治疗的研究现状[J]. 中华普通外科杂志, 2022, 37(11):867-870.

Please choose a citation manager

Content to export